期刊文献+

New advances in targeted gastric cancer treatment 被引量:15

New advances in targeted gastric cancer treatment
下载PDF
导出
摘要 Despite a decrease in incidence over past decades,gastric cancer remains a major global health problem. In the more recent period, survival has shown only minor improvement, despite significant advances in diagnostic techniques, surgical and chemotherapeutic approaches, the development of novel therapeutic agents and treatment by multidisciplinary teams. Because multiple genetic mutations, epigenetic alterations, and aberrant molecular signalling pathways are involved in the development of gastric cancers, recent research has attempted to determine the molecular heterogeneity responsible for the processes of carcinogenesis, spread and metastasis. Currently, some novel agents targeting a part of these dysfunctional molecular signalling pathways have already been integrated into the standard treatment of gastric cancer, whereas others remain in phases of investigation within clinical trials. It is essential to identify the unique molecular patterns of tumours and specific biomarkers to develop treatments targeted to the individual tumour behaviour. This review analyses the global impact of gastric cancer, as well as the role of Helicobacter pylori infection and the efficacy of bacterial eradication in preventing gastric cancer development. Furthermore, the paper discusses the currently available targeted treatments and future directions of research using promising novel classes of molecular agents for advanced tumours. Despite a decrease in incidence over past decades, gastric cancer remains a major global health problem. In the more recent period, survival has shown only minor improvement, despite significant advances in diagnostic techniques, surgical and chemotherapeutic approaches, the development of novel therapeutic agents and treatment by multidisciplinary teams. Because multiple genetic mutations, epigenetic alterations, and aberrant molecular signalling pathways are involved in the development of gastric cancers, recent research has attempted to determine the molecular heterogeneity responsible for the processes of carcinogenesis, spread and metastasis. Currently, some novel agents targeting a part of these dysfunctional molecular signalling pathways have already been integrated into the standard treatment of gastric cancer, whereas others remain in phases of investigation within clinical trials. It is essential to identify the unique molecular patterns of tumours and specific biomarkers to develop treatments targeted to the individual tumour behaviour. This review analyses the global impact of gastric cancer, as well as the role of Helicobacter pylori infection and the efficacy of bacterial eradication in preventing gastric cancer development. Furthermore, the paper discusses the currently available targeted treatments and future directions of research using promising novel classes of molecular agents for advanced tumours.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第30期6776-6799,共24页 世界胃肠病学杂志(英文版)
关键词 GASTRIC cancer HELICOBACTER PYLORI infection Chemotherapy TARGETED therapy Clinical trials NEW TREAT Gastric cancer Helicobacter pylori infection Chemotherapy Targeted therapy Clinical trials New treatment advances
  • 相关文献

参考文献263

  • 1Cisplatin and Irinotecan Chemotherapy,Followed by ZD 1839 (Iressa)in Patients With Esophageal or Gastric Carcinomas. https://www.clinicaltrials.gov/ct2/show/NCT00215995 .
  • 2Lutzky J,Antonia SJ,Blake-Haskins A,et al.A phase 1 study of MEDI4736,an anti-PD-L1 antibody,in patients with advanced solid tumors. Journal of Clinical Oncology . 2014
  • 3Muro K,Bang Y,Shankaran V,Geva R,Catenacci DVT,Gupta S,Eder JP,Berger R,Gonzalez EJ,Pulini J,Ray AB,Dolled-Filhart M,Emancipator K,Pathiraja K,Shu X,Koshiji MR,Cheng J,Chung HC.A phase 1b study of pembrolizumab (Pembro;MK-3475)in patients (Pts)with advanced gastric cancer. Annals of Oncology . 2014
  • 4Le DT,Bendell JC,Calvo E,Kim JW,Ascierto PA,Sharma P,Ott PA,Bono P,Jaeger D,Jeffry Evans TR,De Braud FG,Chau I,Christensen O,Harbison C,Lin CS,Janjigian YY.Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M)gastric or gastroesophageal junction cancer (GC/GEC):Results from the Check Mate-032 study. Journal of Clinical Oncology . 2016
  • 5Shah MA,Wainberg ZA,Catenacci DV,Hochster HS,Ford J,Kunz P,Lee FC,Kallender H,Cecchi F,Rabe DC,Keer H,Martin AM,Liu Y,Gagnon R,Bonate P,Liu L,Gilmer T,Bottaro DP.Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089),cMET/VEGFR2 inhibitor,in patients with metastatic gastric cancer. PLoS One . 2013
  • 6Jhawer MP,Kindler HL,Wainberg ZA,Ford J,Kunz P,Tang K,McCallum S,Kallender H,Shah MA.Assessment of two dosing schedules of GSK1363089 (GSK089),a dual MET/VEGFR2 inhibitor in metastatic gastric cancer (GC):Interim results of a multicenter phase II study. Journal of Clinical Oncology . 2009
  • 7Shah MA,Bang Y-J,Lordick F,Tabernero J,Chen M,Hack SP,Phan SC,Shames DS,Cunningham D.MET Gastric:A phase III study of onartuzumab plus m FOLFOX6 in patients with metastatic HER2-negative (HER2-)and MET-positive (MET)adenocarcinoma of the stomach or gastroesophageal junction (GEC). Journal of Clinical Oncology . 2015
  • 8Oliner KS,Tang R,Anderson A,et al.Evaluation of MET pathway biomarkers in a phaseⅡstudy of rilotumumab (R,AMG 102)or placebo (P)in combination with epirubicin,cisplatin,and capecitabine (ECX)in patients (pts)with locally advanced or metastatic gastric (G)or esophagogastric junction (EGJ). Journal of Clinical Oncology . 2012
  • 9Qin S,Li J.Phase III study of apatinib in advanced gastric cancer:a randomized,double-blind,placebo-controlled trial. Journal of Clinical Oncology . 2014
  • 10Li J,Qin S,Xu J,Guo W,Xiong J,Bai Y,Sun G,Yang Y,Wang L,Xu N,Cheng Y,Wang Z,Zheng L,Tao M,Zhu X,Ji D,Liu X,Yu H.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebocontrolled,parallel-arm,phase II trial. Journal of Clinical Oncology . 2013

二级参考文献48

  • 1Network NCC. NCCN Clinical Practice Guidelines in Oncology:Gastric Cancer, 2015.
  • 2Snyder RA, Penson DF, Ni S, Koyama T, Merchant NB. Trends inthe use of evidence-based therapy for resectable gastric cancer. JSurg Oncol 2014; 110: 285-290 [PMID: 24891231 DOI: 10.1002/jso.23635].
  • 3Hallissey MT, Dunn JA, Ward LC, Allum WH. The secondBritish Stomach Cancer Group trial of adjuvant radiotherapy orchemotherapy in resectable gastric cancer: five-year follow-up.Lancet 1994; 343: 1309-1312 [PMID: 7910321].
  • 4Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, EstesNC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL,Jessup JM, Martenson JA. Chemoradiotherapy after surgerycompared with surgery alone for adenocarcinoma of the stomachor gastroesophageal junction. N Engl J Med 2001; 345: 725-730[PMID: 11547741 DOI: 10.1056/NEJMoa010187].
  • 5Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC,Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM,Stemmermann GN, Blanke CD, Macdonald JS. Updated analysisof SWOG-directed intergroup study 0116: a phase III trial ofadjuvant radiochemotherapy versus observation after curativegastric cancer resection. J Clin Oncol 2012; 30: 2327-2333 [PMID:22585691 DOI: 10.1200/JCO.2011.36.7136].
  • 6Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY,Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, JungSH, Park CK, Kim KM, Kang WK. Phase III trial comparingcapecitabine plus cisplatin versus capecitabine plus cisplatinwith concurrent capecitabine radiotherapy in completely resectedgastric cancer with D2 lymph node dissection: the ARTIST trial. JClin Oncol 2012; 30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953].
  • 7Dikken JL, van Sandick JW, Maurits Swellengrebel HA, LindPA, Putter H, Jansen EP, Boot H, van Grieken NC, van de VeldeCJ, Verheij M, Cats A. Neo-adjuvant chemotherapy followed bysurgery and chemotherapy or by surgery and chemoradiotherapyfor patients with resectable gastric cancer (CRITICS). BMC Cancer2011; 11: 329 [PMID: 21810227 DOI: 10.1186/1471-2407-11-329].
  • 8Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, LeeKW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS,Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatinfor gastric cancer after D2 gastrectomy (CLASSIC): a phase 3open-label, randomised controlled trial. Lancet 2012; 379: 315-321[PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4].
  • 9Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M,Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, ImamuraH, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvantchemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289 DOI:10.1056/NEJMoa072252].
  • 10Cunningham D, Allum WH, Stenning SP, Thompson JN, Vande Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, IvesonTJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ.Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID:16822992 DOI: 10.1056/NEJMoa055531].

共引文献154

同被引文献175

引证文献15

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部